醋酸钙片治疗腹膜透析患者高磷血症的疗效观察

目的：观察醋酸钙片治疗腹膜透析患者高磷血症的临床疗效。方法：41例CAPD腹膜透析伴有高磷血症患者，口服醋酸钙片治疗，观察8周。检测治疗前、治疗2周、4周和8周血磷、血钙、碱性磷酸酶和全段甲状旁腺激素等。结果：与治疗前比较，治疗2周、4周、8周血磷明显下降，差异有统计学意义（P值〈0.05）；与治疗前比较，治疗2、4、8周校正血钙、白蛋白、血红蛋白、血肌酐、全段甲状旁腺激素和碱性磷酸酶差异均无统计学意义（P〉0.05）。醋酸钙片治疗高磷血症总有效率82.93％，轻度不良反应发生率4.88％，高钙血症2例，发生率4.88％。结论：醋酸钙片治疗腹膜透析患者高磷血症具有明显疗效且安全。

Efficacy and Safety of Calcium Acetate for the Treatment of Peritoneal Dialysis with Hyperphosphatemia

Objective：To evaluate the efficacy and safety of calcium acetate for the treatment of peritoneal dialysis patients with hyperphosphatemia. Methods：41 cases Continuous ambulatory peritoneal dialysis patients with hyperphosphatemia, received calcium acetate treatment for 8 weeks. Serum phosphorus, calcium, alkaline phosphatase and intact parathyroid hormone （iPTH）were assessed at 2, 4 and 8 weeks after treatment. Results：Serum phosphorus was declined significantly after 2 ,4 and 8 weeks of treatment compared with the baseline （P 〈 0.05 ）, while the levels of serum calcium, hemoglobin, albumin, serum creatinine and intact parathyroid hormone showed no significant difference（P 〉 0.05 ）. The total effective rate was 82.93% after treatment, while the incidence of mild adverse reaction was 4.88%, and hypercalcemia in 2 patients was observed, the incidence was 4.88%. Conclusion ：Calcium acetate for the treatment of peritoneal dialysis patients with hyperphosphatemia has obvious efficacy and safety.